NCT02715531 2021-07-09
A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
Clinical Trials
22 trialsNCT00786669 2021-02-10
VITAC
Children's Hospital Medical Center, Cincinnati
Phase 1 Completed
NCT00295503 2020-10-20
Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT02857920 2020-09-14
Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors
Fuda Cancer Hospital, Guangzhou
Phase 1/2 Completed
NCT00390156 2020-07-28
Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors
University of California, San Francisco
Phase 1 Completed
NCT01332721 2018-12-05
Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated
Tracon Pharmaceuticals Inc.
Phase 1 Completed
NCT00861419 2017-02-08
To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.
Amgen
Phase 1 Completed
NCT00416637 2016-07-07
Bevacizumab in Treating Patients With Advanced Solid Tumors
Duke University
Phase 1 Completed
NCT00888043 2015-03-11
CNTO95/Avastin
Duke University
Phase 1 Completed
NCT00781846 2015-02-13
Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00276575 2014-11-19
Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid Tumors
Duke University
Phase 1 Completed
NCT00586443 2014-11-19
BEP
Duke University
Phase 1 Completed
NCT00357318 2014-02-24
Bevacizumab and Sunitinib in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00027703 2014-02-11
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00085111 2013-06-05
Bevacizumab in Treating Young Patients With Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00550927 2013-05-15
Enzastaurin and Bevacizumab in Treating Patients With Locally Advanced or Metastatic Cancer
Eli Lilly and Company
Phase 1 Completed
NCT00586092 2013-04-08
A Phase I Study of ABT-510 in Combination With Bevacizumab in Advanced Solid Tumors
Duke University
Phase 1 Completed
NCT01055795 2012-12-24
BEL
Duke University
Phase 1 Completed
NCT00005061 2012-07-18
Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Solid Tumors
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1 Completed
NCT00137826 2011-12-26
Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00407459 2011-09-02
Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma
Istituto Clinico Humanitas
Phase 2 Completed
NCT00556088 2010-12-30
LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid Tumors
SCRI Development Innovations, LLC
Phase 1 Completed